Evidence map›Paper›PMID 25553977›Full record

ArticleSchizophrenia research2015

Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies.

Allen D Radant, Steven P Millard, David L Braff, Monica E Calkins, Dorcas J Dobie, Robert Freedman, Michael F Green, Tiffany A Greenwood, Raquel E Gur, Ruben C Gur and 14 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Allen D RadantDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; Department of Veteran affairs (DVA), VISN-20, Mental Health Services, Seattle, WA, USA.
Steven P MillardDVA, VISN-20, Mental Illness Research, Education, and Clinical Center (MIRECC), Seattle, WA, USA.
David L BraffDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA; DVA, VISN-22 MIRECC, San Diego Healthcare System, San Diego, CA, USA.
Monica E CalkinsDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Dorcas J DobieDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; DVA, VISN-20, Mental Illness Research, Education, and Clinical Center (MIRECC), Seattle, WA, USA.
Robert FreedmanDepartment of Psychiatry, University of Colorado Health Sciences Center, Aurora, CO, USA.
Michael F GreenDepartment of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Tiffany A GreenwoodDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA.
Raquel E GurDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Ruben C GurDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Laura C LazzeroniDepartment of Biostatistics, Stanford University, Palo Alto, CA, USA.
Gregory A LightDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA.
Sean P MeichleDVA, VISN-20, Mental Illness Research, Education, and Clinical Center (MIRECC), Seattle, WA, USA.
Keith H NuechterleinDepartment of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ann OlincyDepartment of Psychiatry, University of Colorado Health Sciences Center, Aurora, CO, USA.
Larry J SeidmanMassachusetts Mental Health Center, Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Psychiatry, Harvard Institute of Psychiatric Epidemiology and Genetics, Boston, MA, USA.
Larry J SieverDepartment of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA; DVA, VISN-3, MIRECC, James J. Peters VA Medical Center, Bronx, NY, USA.
Jeremy M SilvermanDepartment of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA; DVA, VISN-3, MIRECC, James J. Peters VA Medical Center, Bronx, NY, USA.
William S StoneMassachusetts Mental Health Center, Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Psychiatry, Harvard Institute of Psychiatric Epidemiology and Genetics, Boston, MA, USA.
Neal R SwerdlowDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA.
Catherine A SugarDepartment of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ming T TsuangDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA.
Bruce I TuretskyDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Debby W TsuangDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; DVA, VISN-20, Geriatric Research, Education, and Clinical Center, Seattle, WA, USA.

Funding

The Genetics of Endophenotypes and SchizophreniaR01MH065571 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 2003 to 2013
$7.0M
The Genetics of Endophenotypes and SchizophreniaR01MH065578 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 2003 to 2013
$4.2M
The Genetics of Endophenotypes and SchizophreniaR01MH065554 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SIEVER, LARRY J · 2003 to 2013
$4.1M
Genetics of Endophenotypes and SchizophreniaR01MH065558 · NIMH · UNIVERSITY OF WASHINGTON · PI TSUANG, DEBBY WEN · 2003 to 2013
$3.7M
The Genetics of Endophenotypes and SchizophreniaR01MH065707 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GREEN, MICHAEL F. · 2003 to 2013
$3.6M
The Genetics of Endophenotypes and SchizophreniaR01MH065562 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SEIDMAN, LARRY J · 2003 to 2007
$2.6M
The Genetics of Endophenotypes and SchizophreniaR01MH065588 · NIMH · UNIVERSITY OF COLORADO DENVER · PI OLINCY, ANN · 2003 to 2007
$2.2M
6/6 - The Genetics of Endophenotypes and SchizophreniaR01MH086135 · NIMH · STANFORD UNIVERSITY · PI LAZZERONI, LAURA C. · 2010 to 2013
$1.3M
NIMH NIH HHS R01 MH065554NIMH NIH HHS R01 MH065558NIMH NIH HHS R01 MH065562NIMH NIH HHS R01 MH065571NIMH NIH HHS R01 MH065578NIMH NIH HHS R01 MH065588NIMH NIH HHS R01 MH065707NIMH NIH HHS R01 MH086135NIMH NIH HHS R01 MH65554NIMH NIH HHS R01 MH65558NIMH NIH HHS R01 MH65562NIMH NIH HHS R01 MH65571NIMH NIH HHS R01 MH65578NIMH NIH HHS R01 MH65588NIMH NIH HHS R01 MH65707
6 · The paper itself

Abstract

The impaired ability to make correct antisaccades (i.e., antisaccade performance) is well documented among schizophrenia subjects, and researchers have successfully demonstrated that antisaccade performance is a valid schizophrenia endophenotype that is useful for genetic studies. However, it is unclear how the ascertainment biases that unavoidably result from recruitment differences in schizophrenia subjects identified in family versus case-control studies may influence patient-control differences in antisaccade performance. To assess the impact of ascertainment bias, researchers from the Consortium on the Genetics of Schizophrenia (COGS) compared antisaccade performance and antisaccade metrics (latency and gain) in schizophrenia and control subjects from COGS-1, a family-based schizophrenia study, to schizophrenia and control subjects from COGS-2, a corresponding case-control study. COGS-2 schizophrenia subjects were substantially older; had lower education status, worse psychosocial function, and more severe symptoms; and were three times more likely to be a member of a multiplex family than COGS-1 schizophrenia subjects. Despite these variations, which were likely the result of ascertainment differences (as described in the introduction to this special issue), the effect sizes of the control-schizophrenia differences in antisaccade performance were similar in both studies (Cohen's d effect size of 1.06 and 1.01 in COGS-1 and COGS-2, respectively). This suggests that, in addition to the robust, state-independent schizophrenia-related deficits described in endophenotype studies, group differences in antisaccade performance do not vary based on subject ascertainment and recruitment factors.

Indexed as

Psychomotor PerformanceSaccadesSchizophrenic PsychologyAdolescentAdultAgedCase-Control StudiesCohort StudiesEndophenotypesEpidemiologic Research DesignEye Movement MeasurementsFamilyFemaleHumansMaleMiddle AgedAntisaccade taskRecruitment

Identifiers

PMID25553977
PMCPMC4382408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.